PG (6550) reported revenue of NT$1.9 million for Oct 2026, +894.8% year on year and -69.9% from the previous month. Revenue for Jan–Oct 2026 was NT$53.2 million (+52.9% year on year).
In Oct 2026, it ranked No. 145 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$1.9 million | +894.8% | -69.9% |
| Sep 2026 | NT$6.3 million | -52.2% | +40.2% |
| Aug 2026 | NT$4.5 million | +202.6% | — |
| Jul 2026 | -NT$3.6 million | -211.7% | -193.8% |
| Jun 2026 | NT$3.8 million | -19.0% | +137.8% |
| May 2026 | NT$1.6 million | — | -4.0% |
| Apr 2026 | NT$1.7 million | -57.1% | +5.7% |
| Mar 2026 | NT$1.6 million | -59.7% | -90.7% |
| Feb 2026 | NT$16.9 million | +322.9% | -8.1% |
| Jan 2026 | NT$18.4 million | +1,275.3% | +493.0% |
| Dec 2025 | NT$3.1 million | -40.7% | +11.5% |
| Nov 2025 | NT$2.8 million | -81.3% | +1,359.7% |
| Oct 2025 | NT$191,000 | -98.8% | -98.6% |
| Sep 2025 | NT$13.2 million | +310.1% | +787.1% |
| Aug 2025 | NT$1.5 million | -60.6% | -53.5% |
| Jul 2025 | NT$3.2 million | -21.6% | -31.9% |
| Jun 2025 | NT$4.7 million | -5.8% | — |
| May 2025 | -NT$1.1 million | -115.5% | -127.7% |
| Apr 2025 | NT$3.9 million | -80.6% | -0.8% |
| Mar 2025 | NT$3.9 million | -19.3% | -2.2% |
| Feb 2025 | NT$4 million | -71.3% | +199.0% |
| Jan 2025 | NT$1.3 million | -85.1% | -74.4% |
| Dec 2024 | NT$5.2 million | +23.9% | -64.9% |
| Nov 2024 | NT$14.9 million | — | -6.7% |
| Oct 2024 | NT$16 million | +2,490.9% | +398.2% |
Jan–Oct 2026 cumulative: NT$53.2 million (+52.9% YoY)
Other Biotech & Medical companies
Compare with peers: PG vs PEC / PG vs Lotus Pharm / PG vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
子公司CDMO及自有產品收入下降導致兩期差異
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16